Trials / Completed
CompletedNCT05432492
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
A Phase II Study of AK112 (PD-1/VEGF Bispecific) in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 | IV infusion, specified dose on specified days |
Timeline
- Start date
- 2022-08-03
- Primary completion
- 2025-04-30
- Completion
- 2025-06-14
- First posted
- 2022-06-27
- Last updated
- 2026-03-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05432492. Inclusion in this directory is not an endorsement.